Search

Your search keyword '"Kerbel, Robert S."' showing total 961 results
Start Over Author "Kerbel, Robert S." Publication Year Range Last 50 years
961 results on '"Kerbel, Robert S."'

2. Potentiating Salvage Radiotherapy in Radiorecurrent Prostate Cancer Through Anti-CTLA4 Therapy: Implications from a Syngeneic Model.

Author

Wang, Hanzhi, Gong, Linsey, Huang, Xiaoyong, White, Stephanie D., Chung, Hans T., Vesprini, Danny, Petchiny, Tera N., Fokas, Emmanouil, He, Hansen, Kerbel, Robert S., and Liu, Stanley K.

Abstract

Simple Summary: Advanced prostate cancer (PCa) is a prominent contributor to cancer-related fatalities and is associated with significant morbidity and mortality. Currently, addressing the local recurrence of the disease after radiation therapy (RT) poses a significant clinical challenge. We established the first syngeneic model of radiorecurrent PCa to evaluate the effectiveness of immune checkpoint inhibitors (ICIs) in combination with high-dose ionizing radiation (IR). We observed an enhanced anti-tumor response, which led to a delay in tumor growth and, in some cases, a complete elimination of tumors when combining IR with anti-CTLA4. This improvement was linked to an enhanced activation of total T cells, CD4+ helper T cells, and CD8+ cytotoxic T cells in both the draining lymph node and tumor. These results hold substantial potential for translation into clinical practice, serving as a proof of concept for the application of brachytherapy and immune checkpoint inhibitors (ICIs) in cases of recurrent disease. High-risk prostate cancer (PCa) is a leading cause in cancer death and can elicit significant morbidity and mortality. Currently, the salvage of local disease recurrence after radiation therapy (RT) is a major clinical problem. Immune checkpoint inhibitors (ICIs), which enhance immune activation, have demonstrated clinical therapeutic promise in combination with ionizing radiation (IR) in certain advanced cancers. We generated the TRAMP-C2 HF radiorecurrent syngeneic mouse model to evaluate the therapeutic efficacy of ICIs in combination with RT. The administration of anti-PDL1 and/or anti-CTLA4 did not achieve a significant tumor growth delay compared to the control. The combination of IR and anti-PDL1 did not yield additional a growth delay compared to IR and the isotype control. Strikingly, a significant tumor growth delay and complete cure in one-third of the mice were seen with the combination of IR and anti-CTLA4. Immune cells in tumor-draining lymph nodes and tumor-infiltrating lymphocytes from mice treated with IR and anti-CTLA4 demonstrated an upregulation of genes in T-cell functions and enrichment in both CD4+ and CD8+ T-cell populations compared to mice given IR and the isotype control. Taken together, these results indicate enhancement of T-cell response in radiorecurrent PCa by IR and anti-CTLA4. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Consensus guidelines for the use and interpretation of angiogenesis assays

Author

Nowak-Sliwinska, Patrycja, Alitalo, Kari, Allen, Elizabeth, Anisimov, Andrey, Aplin, Alfred C, Auerbach, Robert, Augustin, Hellmut G, Bates, David O, van Beijnum, Judy R, Bender, R Hugh F, Bergers, Gabriele, Bikfalvi, Andreas, Bischoff, Joyce, Böck, Barbara C, Brooks, Peter C, Bussolino, Federico, Cakir, Bertan, Carmeliet, Peter, Castranova, Daniel, Cimpean, Anca M, Cleaver, Ondine, Coukos, George, Davis, George E, De Palma, Michele, Dimberg, Anna, Dings, Ruud PM, Djonov, Valentin, Dudley, Andrew C, Dufton, Neil P, Fendt, Sarah-Maria, Ferrara, Napoleone, Fruttiger, Marcus, Fukumura, Dai, Ghesquière, Bart, Gong, Yan, Griffin, Robert J, Harris, Adrian L, Hughes, Christopher CW, Hultgren, Nan W, Iruela-Arispe, M Luisa, Irving, Melita, Jain, Rakesh K, Kalluri, Raghu, Kalucka, Joanna, Kerbel, Robert S, Kitajewski, Jan, Klaassen, Ingeborg, Kleinmann, Hynda K, Koolwijk, Pieter, Kuczynski, Elisabeth, Kwak, Brenda R, Marien, Koen, Melero-Martin, Juan M, Munn, Lance L, Nicosia, Roberto F, Noel, Agnes, Nurro, Jussi, Olsson, Anna-Karin, Petrova, Tatiana V, Pietras, Kristian, Pili, Roberto, Pollard, Jeffrey W, Post, Mark J, Quax, Paul HA, Rabinovich, Gabriel A, Raica, Marius, Randi, Anna M, Ribatti, Domenico, Ruegg, Curzio, Schlingemann, Reinier O, Schulte-Merker, Stefan, Smith, Lois EH, Song, Jonathan W, Stacker, Steven A, Stalin, Jimmy, Stratman, Amber N, Van de Velde, Maureen, van Hinsbergh, Victor WM, Vermeulen, Peter B, Waltenberger, Johannes, Weinstein, Brant M, Xin, Hong, Yetkin-Arik, Bahar, Yla-Herttuala, Seppo, Yoder, Mervin C, and Griffioen, Arjan W

Subjects
Biochemistry and Cell Biology, Biological Sciences, Regenerative Medicine, Animals, Biological Assay, Guidelines as Topic, Humans, Mice, Neoplasms, Neovascularization, Pathologic, Angiogenesis, Aortic ring, Endothelial cell migration, Proliferation, Microfluidic, Zebrafish, Chorioallantoic membrane, Vascular network, Intussusceptive angiogenesis, Retinal vasculature, Corneal angiogenesis, Hindlimb ischemia, Myocardial angiogenesis, Recombinant proteins, Tip cells, Plug assay, Vessel co-option, Clinical Sciences, Pharmacology and Pharmaceutical Sciences, Oncology & Carcinogenesis, Biochemistry and cell biology
Abstract

The formation of new blood vessels, or angiogenesis, is a complex process that plays important roles in growth and development, tissue and organ regeneration, as well as numerous pathological conditions. Angiogenesis undergoes multiple discrete steps that can be individually evaluated and quantified by a large number of bioassays. These independent assessments hold advantages but also have limitations. This article describes in vivo, ex vivo, and in vitro bioassays that are available for the evaluation of angiogenesis and highlights critical aspects that are relevant for their execution and proper interpretation. As such, this collaborative work is the first edition of consensus guidelines on angiogenesis bioassays to serve for current and future reference.

Published
2018

14. Abstract 3998: Metronomic gemcitabine plus neratinib effectively inhibits the growth of human Her-2 positive breast cancer cells intracranially implanted into immunodeficient mice

Author

Batson, Serina, primary, Sanchez, Alejandro, additional, Padilla, Hector M., additional, Prospero, Diana L., additional, Lugo, Brenda, additional, Lopez, Valeria V., additional, Estrada, Daniella E., additional, De Avila, Nydia, additional, Darvishi, Saeedeh, additional, Levario, Arlene, additional, Man, Shan, additional, Xu, Ping, additional, Kerbel, Robert S., additional, Bocci, Guido, additional, and Francia, Giulio, additional

Published
2023
Full Text
View/download PDF

15. Supplementary Figure Legends 1-2 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis

Author

Francia, Giulio, primary, Shaked, Yuval, primary, Hashimoto, Kae, primary, Sun, John, primary, Yin, Melissa, primary, Cesta, Carolyn, primary, Xu, Ping, primary, Man, Shan, primary, Hackl, Christina, primary, Stewart, Julie, primary, Uhlik, Mark, primary, Dantzig, Anne H., primary, Foster, F. Stuart, primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

16. Data from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis

Author

Francia, Giulio, primary, Shaked, Yuval, primary, Hashimoto, Kae, primary, Sun, John, primary, Yin, Melissa, primary, Cesta, Carolyn, primary, Xu, Ping, primary, Man, Shan, primary, Hackl, Christina, primary, Stewart, Julie, primary, Uhlik, Mark, primary, Dantzig, Anne H., primary, Foster, F. Stuart, primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure 1 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis

Author

Francia, Giulio, primary, Shaked, Yuval, primary, Hashimoto, Kae, primary, Sun, John, primary, Yin, Melissa, primary, Cesta, Carolyn, primary, Xu, Ping, primary, Man, Shan, primary, Hackl, Christina, primary, Stewart, Julie, primary, Uhlik, Mark, primary, Dantzig, Anne H., primary, Foster, F. Stuart, primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Video 3 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis

Author

Francia, Giulio, primary, Shaked, Yuval, primary, Hashimoto, Kae, primary, Sun, John, primary, Yin, Melissa, primary, Cesta, Carolyn, primary, Xu, Ping, primary, Man, Shan, primary, Hackl, Christina, primary, Stewart, Julie, primary, Uhlik, Mark, primary, Dantzig, Anne H., primary, Foster, F. Stuart, primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

22. Supplementary materials and methods and legends for Supplementary Figures and Tables from Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors

Author

Kuczynski, Elizabeth A., primary, Krueger, Janna, primary, Chow, Annabelle, primary, Xu, Ping, primary, Man, Shan, primary, Sundaravadanam, Yogi, primary, Miller, Jessica K., primary, Krzyzanowski, Paul M., primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Video 4 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis

Author

Francia, Giulio, primary, Shaked, Yuval, primary, Hashimoto, Kae, primary, Sun, John, primary, Yin, Melissa, primary, Cesta, Carolyn, primary, Xu, Ping, primary, Man, Shan, primary, Hackl, Christina, primary, Stewart, Julie, primary, Uhlik, Mark, primary, Dantzig, Anne H., primary, Foster, F. Stuart, primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Video 2 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis

Author

Francia, Giulio, primary, Shaked, Yuval, primary, Hashimoto, Kae, primary, Sun, John, primary, Yin, Melissa, primary, Cesta, Carolyn, primary, Xu, Ping, primary, Man, Shan, primary, Hackl, Christina, primary, Stewart, Julie, primary, Uhlik, Mark, primary, Dantzig, Anne H., primary, Foster, F. Stuart, primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure 2 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis

Author

Francia, Giulio, primary, Shaked, Yuval, primary, Hashimoto, Kae, primary, Sun, John, primary, Yin, Melissa, primary, Cesta, Carolyn, primary, Xu, Ping, primary, Man, Shan, primary, Hackl, Christina, primary, Stewart, Julie, primary, Uhlik, Mark, primary, Dantzig, Anne H., primary, Foster, F. Stuart, primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Video 1 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis

Author

Francia, Giulio, primary, Shaked, Yuval, primary, Hashimoto, Kae, primary, Sun, John, primary, Yin, Melissa, primary, Cesta, Carolyn, primary, Xu, Ping, primary, Man, Shan, primary, Hackl, Christina, primary, Stewart, Julie, primary, Uhlik, Mark, primary, Dantzig, Anne H., primary, Foster, F. Stuart, primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

45. Data from Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer

Author

Pham, Elizabeth, primary, Yin, Melissa, primary, Peters, Christian G., primary, Lee, Christina R., primary, Brown, Donna, primary, Xu, Ping, primary, Man, Shan, primary, Jayaraman, Lata, primary, Rohde, Ellen, primary, Chow, Annabelle, primary, Lazarus, Douglas, primary, Eliasof, Scott, primary, Foster, F. Stuart, primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

47. Supplemental Figures 1-5 and Methods from Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer

Author

Pham, Elizabeth, primary, Birrer, Michael J., primary, Eliasof, Scott, primary, Garmey, Edward G., primary, Lazarus, Douglas, primary, Lee, Christina R., primary, Man, Shan, primary, Matulonis, Ursula A., primary, Peters, Christian G., primary, Xu, Ping, primary, Krasner, Carolyn, primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

48. Supplemental Figures S1-S6 from Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer

Author

Pham, Elizabeth, primary, Yin, Melissa, primary, Peters, Christian G., primary, Lee, Christina R., primary, Brown, Donna, primary, Xu, Ping, primary, Man, Shan, primary, Jayaraman, Lata, primary, Rohde, Ellen, primary, Chow, Annabelle, primary, Lazarus, Douglas, primary, Eliasof, Scott, primary, Foster, F. Stuart, primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results